These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1386 related articles for article (PubMed ID: 29653971)

  • 1. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
    Jiang Y; Liu Q; Wang G; Zhang J; Zhu Z; Chen X
    Clin Nucl Med; 2023 Jun; 48(6):e289-e293. PubMed ID: 37075254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog
    Liu Q; Cheng Y; Zang J; Sui H; Wang H; Jacobson O; Zhu Z; Chen X
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):947-957. PubMed ID: 31832728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[
    Kamaldeep ; Loharkar S; Das T; Basu S; Banerjee S
    Cancer Biother Radiopharm; 2022 Apr; 37(3):214-225. PubMed ID: 34910891
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of peptide receptor radionuclide therapy with
    Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
    Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of [
    Njotu FN; Ketchemen JP; Tikum AF; Babeker H; Gray BD; Pak KY; Uppalapati M; Fonge H
    J Nucl Med; 2024 Apr; 65(4):533-539. PubMed ID: 38485273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Single Low-dose
    Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X
    Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage PRRT with
    Rudisile S; Gosewisch A; Wenter V; Unterrainer M; Böning G; Gildehaus FJ; Fendler WP; Auernhammer CJ; Spitzweg C; Bartenstein P; Todica A; Ilhan H
    BMC Cancer; 2019 Aug; 19(1):788. PubMed ID: 31395036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.
    Wild D; Fani M; Fischer R; Del Pozzo L; Kaul F; Krebs S; Fischer R; Rivier JE; Reubi JC; Maecke HR; Weber WA
    J Nucl Med; 2014 Aug; 55(8):1248-52. PubMed ID: 24963127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal Imaging of 2-Cycle PRRT with
    Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
    J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
    Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
    Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of
    Liu Q; Zang J; Sui H; Ren J; Guo H; Wang H; Wang R; Jacobson O; Zhang J; Cheng Y; Zhu Z; Chen X
    J Nucl Med; 2021 Mar; 62(3):386-392. PubMed ID: 32826319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution, Pharmacokinetics, and Dosimetry of
    Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
    J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized kidney dosimetry in
    Hou X; Zhao W; Beauregard JM; Celler A
    Phys Med Biol; 2019 Aug; 64(17):175004. PubMed ID: 31456584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.